Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

Fig. 3

Sequencing of treatment in patients diagnosed with stage IIIB–IV NSCLC in 2015–2016 with NSQ (a) or SQ (b). NSCLC non-small cell lung cancer, NSQ non-squamous cell carcinoma, SQ squamous cell carcinoma, LoT line of therapy, MAB monoclonal antibody, TKI tyrosine kinase inhibitor, DoT duration of therapy, IQR interquartile range, TTNT time from SACT initiation to next treatment or death, NA not available, NE not evaluable

Back to article page